MCID: OVR059
MIFTS: 53

Ovary Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovary Adenocarcinoma

MalaCards integrated aliases for Ovary Adenocarcinoma:

Name: Ovary Adenocarcinoma 12 15
Ovarian Adenocarcinoma 12 58 6 17 71
Adenocarcinoma of the Ovary 12
Adenocarcinoma of Ovary 58
Ovarian Adenoacanthoma 12

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:3713
NCIt 49 C7700
ICD10 via Orphanet 33 C56
UMLS via Orphanet 72 C0948216
Orphanet 58 ORPHA213504
UMLS 71 C0948216

Summaries for Ovary Adenocarcinoma

Disease Ontology : 12 An ovarian carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Ovary Adenocarcinoma, also known as ovarian adenocarcinoma, is related to endometrioid ovary carcinoma and ovarian mucinous adenocarcinoma. An important gene associated with Ovary Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Paclitaxel and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and endothelial, and related phenotypes are abdominal distention and episodic abdominal pain

Related Diseases for Ovary Adenocarcinoma

Diseases related to Ovary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 504)
# Related Disease Score Top Affiliating Genes
1 endometrioid ovary carcinoma 33.0 TP53 KRAS CTNNB1 ARID1A
2 ovarian mucinous adenocarcinoma 33.0 SERPINA3 KRT7 CEACAM5
3 ovarian cystadenocarcinoma 32.8 TP53 SERPINA3 MIR744 MIR30A MIR17 MIR1307
4 appendix adenocarcinoma 31.8 KRT7 KRAS HRAS CEACAM5
5 mucinous adenocarcinoma 31.8 TP53 KRT7 KRAS ERBB2 CEACAM5
6 serous cystadenocarcinoma 31.5 TP53 MIR30A KRT7 KRAS HRAS ESS2
7 adenocarcinoma 31.5 TP53 KRT7 KRAS HRAS ERBB2 CTNNB1
8 adenofibroma 31.4 TP53 KRT7 ARID1A
9 papillary adenocarcinoma 31.3 TP53 MIR30A KRT7 KRAS HRAS ERBB2
10 cystadenocarcinoma 31.3 TP53 SERPINA3 MIR30A KRT7 HRAS ERBB2
11 papillary serous adenocarcinoma 31.2 TP53 MIR30A KRT7 KRAS CEACAM5 BRCA1
12 adenoma 31.2 TP53 KRT7 KRAS CTNNB1
13 ovarian cancer 31.2 TP53 SERPINA3 MIR30A MIR17 MIR135A1 KRT7
14 cystic teratoma 31.1 TP53 KRT7 KRAS CEACAM5
15 small cell carcinoma 31.1 TP53 KRT7 KRAS
16 cystadenoma 31.0 SERPINA3 KRT7 CEACAM5 BRCA1
17 pseudomyxoma peritonei 31.0 TP53 KRT7 KRAS CTNNB1 CEACAM5
18 teratoma 31.0 TP53 KRT7 KRAS CTNNB1 CEACAM5
19 secretory meningioma 30.9 SERPINA3 KRT7 CEACAM5
20 mucinous cystadenocarcinoma 30.8 SERPINA3 KRT7 CEACAM5
21 ovarian serous carcinoma 30.8 TP53 KRAS ERBB2
22 embryonal sarcoma 30.8 TP53 SERPINA3 CTNNB1
23 endometrial hyperplasia 30.8 TP53 KRAS CTNNB1 ARID1A
24 fallopian tube carcinoma 30.8 TP53 ERBB2 BRCA1
25 endocervical adenocarcinoma 30.8 TP53 KRT7 ERBB2 CEACAM5
26 ovarian clear cell carcinoma 30.8 TP53 KRT7 KRAS ARID1A
27 clear cell adenocarcinoma 30.8 TP53 KRT7 ARID1A
28 adenosarcoma 30.8 TP53 SERPINA3 ERBB2
29 ovarian disease 30.8 TP53 MIR30A MIR17 MIR135A1 ERBB2 CTNNB1
30 meningioma, familial 30.8 TP53 SERPINA3 H2AC18 ERBB2 CTNNB1
31 sarcoma 30.7 TP53 SERPINA3 KRAS HRAS CTNNB1 BAX
32 tubular adenocarcinoma 30.7 KRT7 ERBB2 CTNNB1 CEACAM5
33 rectum cancer 30.7 MIR17 MIR135A1 KRAS HRAS CEACAM5
34 squamous cell carcinoma 30.7 TP53 KRT7 HRAS ERBB2 CTNNB1 CEACAM5
35 skin melanoma 30.7 TP53 HRAS H2AC18 ERBB2
36 endometrial adenocarcinoma 30.7 TP53 KRT7 KRAS ERBB2 CTNNB1
37 carcinosarcoma 30.7 TP53 KRT7 KRAS HRAS ERBB2 CTNNB1
38 colorectal adenocarcinoma 30.7 TP53 KRT7 KRAS HRAS ERBB2 CTNNB1
39 breast adenocarcinoma 30.7 TP53 SERPINA3 KRAS H2AC18 ERBB2 BAX
40 endometrial cancer 30.6 TP53 SERPINA3 KRT7 KRAS HRAS ERBB2
41 rhabdomyosarcoma 30.6 TP53 KRAS HRAS CTNNB1 BRCA1
42 melanoma 30.6 TP53 MIR17 KRAS HRAS ERBB2 CTNNB1
43 bladder cancer 30.6 TP53 MIR17 KRAS HRAS ERBB2 CTNNB1
44 peripheral nervous system disease 30.6 TP53 SERPINA3 H2AC18 ERBB2
45 renal cell carcinoma, nonpapillary 30.5 TP53 MIR30A MIR17 MIR135A1 KRT7 HRAS
46 thyroid gland cancer 30.5 TP53 MIR17 KRT7 KRAS HRAS CTNNB1
47 cervical cancer 30.5 TP53 MIR30A MIR17 HRAS ERBB2 CTNNB1
48 ovarian serous cystadenocarcinoma 30.5 TP53 SERPINA3 MIR744 MIR30A MIR17 MIR1307
49 lynch syndrome 30.4 TP53 MIR17 KRAS HRAS H2AC18 ERBB2
50 esophageal cancer 30.4 TP53 MIR30A KRAS INHBA HRAS ERBB2

Graphical network of the top 20 diseases related to Ovary Adenocarcinoma:



Diseases related to Ovary Adenocarcinoma

Symptoms & Phenotypes for Ovary Adenocarcinoma

Human phenotypes related to Ovary Adenocarcinoma:

31 (show all 19)
# Description HPO Frequency HPO Source Accession
1 abdominal distention 31 frequent (33%) HP:0003270
2 episodic abdominal pain 31 frequent (33%) HP:0002574
3 episodic vomiting 31 frequent (33%) HP:0002572
4 nausea 31 frequent (33%) HP:0002018
5 elevated carcinoma antigen 125 level 31 frequent (33%) HP:0031030
6 endometriosis 31 frequent (33%) HP:0030127
7 feeding difficulties 31 occasional (7.5%) HP:0011968
8 ascites 31 occasional (7.5%) HP:0001541
9 intestinal obstruction 31 occasional (7.5%) HP:0005214
10 dysmenorrhea 31 occasional (7.5%) HP:0100607
11 pleural effusion 31 occasional (7.5%) HP:0002202
12 urinary urgency 31 occasional (7.5%) HP:0000012
13 thromboembolism 31 occasional (7.5%) HP:0001907
14 menorrhagia 31 occasional (7.5%) HP:0000132
15 abdominal mass 31 occasional (7.5%) HP:0031500
16 ovarian papillary adenocarcinoma 31 occasional (7.5%) HP:0006774
17 ovarian mucinous tumor 31 occasional (7.5%) HP:0031494
18 cervical lymphadenopathy 31 very rare (1%) HP:0025289
19 elevated carcinoembryonic antigen level 31 very rare (1%) HP:0031029

GenomeRNAi Phenotypes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.72 KRAS
2 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.72 BRCA1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.72 BRCA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.72 ERBB2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 ARID1A BRCA1 ERBB2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.72 ARID1A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.72 ARID1A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.72 ARID1A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.72 BRCA1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.72 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.72 BRCA1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.72 ARID1A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.72 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 ERBB2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.72 ARID1A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.72 ERBB2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.72 ERBB2 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 ARID1A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.72 H2AC18
20 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 ERBB2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.72 ERBB2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.72 H2AC18

MGI Mouse Phenotypes related to Ovary Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.91 ARID1A CTNNB1 ERBB2 HRAS INHBA KRAS
2 limbs/digits/tail MP:0005371 9.87 BAX BRCA1 C1RL CTNNB1 ERBB2 KRAS
3 muscle MP:0005369 9.86 ARID1A BAX BRCA1 CTNNB1 ERBB2 INHBA
4 neoplasm MP:0002006 9.76 ARID1A BAX BRCA1 CTNNB1 ERBB2 HRAS
5 renal/urinary system MP:0005367 9.56 BAX BRCA1 CTNNB1 HRAS INHBA KRAS
6 skeleton MP:0005390 9.32 ARID1A BAX BRCA1 C1RL CTNNB1 ERBB2

Drugs & Therapeutics for Ovary Adenocarcinoma

Drugs for Ovary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
2
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
3
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
4
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6 Immunoglobulins Phase 3
7 Antibodies Phase 3
8 Angiogenesis Inhibitors Phase 3
9 Mitogens Phase 3
10 Immunoglobulins, Intravenous Phase 3
11 Albumin-Bound Paclitaxel Phase 3
12 Endothelial Growth Factors Phase 3
13 Antibodies, Monoclonal Phase 3
14 Tubulin Modulators Phase 3
15 Immunoglobulin G Phase 3
16 Antimetabolites Phase 3
17 Antimitotic Agents Phase 3
18 Antineoplastic Agents, Immunological Phase 3
19
Nintedanib Approved Phase 2 656247-17-5 56843413
20
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
21
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
22
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
23
Oregovomab Investigational Phase 2 213327-37-8
24 Molgramostim Investigational Phase 2 99283-10-0
25 Protein Kinase Inhibitors Phase 2
26 Pharmaceutical Solutions Phase 2
27 Immunologic Factors Phase 2
28 Vaccines Phase 2
29 Anti-HIV Agents Phase 2
30 Adjuvants, Immunologic Phase 2
31 Anti-Infective Agents Phase 2
32 Freund's Adjuvant Phase 2
33 Antiviral Agents Phase 2
34 Anti-Retroviral Agents Phase 2
35
Cisplatin Approved Phase 1 15663-27-1 2767 441203 84093

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
2 A Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of the Safety and Efficacy of OVAREX MabB43.13 in Ovarian Cancer Patients With an Elevated Serum CA 125 But Without Other Evidence of Disease Unknown status NCT00004064 Phase 2
3 OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse: Unknown status NCT00660101 Phase 1, Phase 2
4 Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum Completed NCT01583322 Phase 2 vargatef;placebo
5 A Phase II, Open-Label, Non-Randomized, Multi-Center Pilot Study of Intravenous Taxol, Carboplatin, Bevacizumab Given Every 21 Days in Patients With Newly Diagnosed Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Completed NCT00127920 Phase 2 Avastin
6 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
7 Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies. Active, not recruiting NCT03365791 Phase 2
8 Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary Terminated NCT00001827 Phase 2
9 A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer Withdrawn NCT03281681 Phase 1, Phase 2 VAL-083, Dianhydrogalactitol
10 A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (Ad5-Delta 24 RGD)for Intraperitoneal Delivery in Ovarian and Extraovarian Cancer Patients (Infectivity Enhanced Virotherapy for Ovarian Cancer) Completed NCT00562003 Phase 1 Ad5-delta24RGD
11 Phase I Study of Cisplatin Hyperthermic Intraperitoneal Chemotherapy Dose Escalation After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Previously Treated by Chemotherapy and Completed by Bevacizumab for 15 Months Completed NCT02217956 Phase 1 Cisplatin;Bevacizumab
12 A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy Recruiting NCT03608618 Phase 1
13 The CINSARC Genomic Signature as a Predictor of Resectability of High Grade Serous Ovarian Adenocarcinomas Recruiting NCT04248231
14 The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients Treated With or Without Paclitaxel Regimens Recruiting NCT03019315

Search NIH Clinical Center for Ovary Adenocarcinoma

Genetic Tests for Ovary Adenocarcinoma

Anatomical Context for Ovary Adenocarcinoma

MalaCards organs/tissues related to Ovary Adenocarcinoma:

40
Ovary, Breast, Endothelial, Testes, Lymph Node, Lung, T Cells

Publications for Ovary Adenocarcinoma

Articles related to Ovary Adenocarcinoma:

(show top 50) (show all 1035)
# Title Authors PMID Year
1
Antioxidant, antiproliferative and healing properties of araticum (Annona crassiflora Mart.) peel and seed. 61
32466931 2020
2
Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature. 61
32483276 2020
3
Bevacizumab-induced dysphonia: A case report with brief review of literature. 61
31771464 2020
4
Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines. 61
31241128 2020
5
Identification of Human Ovarian Adenocarcinoma Cells with Cisplatin-resistance by Feature Extraction of Gray Level Co-occurrence Matrix Using Optical Images. 61
32527052 2020
6
Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations. 61
32370213 2020
7
An antibody drug conjugate targeting MUC1 associated carbohydrate CA6, shows promising anti-tumor activities. 61
32451330 2020
8
Prognostic Significance of the MAD1L1 1673 G: A Polymorphism in Ovarian Adenocarcinomas. 61
32488223 2020
9
Characterization of ascites-derived aldehyde dehydrogenase-positive ovarian cancer stem cells isolated from Leghorn chickens. 61
32241506 2020
10
MCL1 regulates cell death, tumor growth and chemosensitivity to sabutoclax in ovarian adenocarcinoma. 61
31754782 2020
11
Identification of Radiation-Dose-Dependent Expressive Genes in Individuals Exposed to External Ionizing Radiation. 61
31910119 2020
12
Stomach gastrin is regulated by sodium via PPAR-α and dopamine D1 receptor. 61
31794424 2020
13
Comparative study of the antitumoral activity of phosphine-thiosemicarbazone gold(I) complexes obtained by different methodologies. 61
31786438 2020
14
Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base. 61
31839340 2020
15
CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. 61
32117253 2020
16
Extended Pelvic Resections as Part of Secondary Cytoreduction for Relapsed Ovarian Adenocarcinoma. 61
31882505 2020
17
Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy. 61
31520887 2019
18
Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin. 61
31817672 2019
19
A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication. 61
31246641 2019
20
Robotic Tumor Debulking off External Iliac Vessels for the Management of Recurrent Ovarian Cancer. 61
31610315 2019
21
GSVD- and tensor GSVD-uncovered patterns of DNA copy-number alterations predict adenocarcinomas survival in general and in response to platinum. 61
31463421 2019
22
Hyperthermia potentiates cisplatin cytotoxicity and negative effects on mitochondrial functions in OVCAR-3 cells. 61
31332716 2019
23
Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells. 61
31029905 2019
24
Fabrication of gold-silver core-shell nanoparticles for performing as ultrabright SERS-nanotags inside human ovarian cancer cells. 61
30974419 2019
25
Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity. 61
31394747 2019
26
Hepatic nontuberculous mycobacterial granulomas in patients with cancer mimicking metastases: an analysis of three cases. 61
31367567 2019
27
Novel half-sandwich rhodium(III) and iridium(III) photosensitizers for dual chemo- and photodynamic therapy. 61
31048016 2019
28
Photodynamic Therapy of Ovarian Carcinoma Cells with Curcumin-Loaded Biodegradable Polymeric Nanoparticles. 61
31208085 2019
29
Effect of electrochemotherapy with betulinic acid or cisplatin on regulation of heat shock proteins in metastatic human carcinoma cells in vitro. 61
31002374 2019
30
Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin. 61
31067739 2019
31
18F-FDG PET/CT of Lung Adenocarcinoma With Ovarian Metastases. 61
30789397 2019
32
α-Mangostin and Apigenin Induced Cell Cycle Arrest and Programmed Cell Death in SKOV-3 Ovarian Cancer Cells. 61
31015899 2019
33
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting. 61
30958459 2019
34
A protein nanocontainer targeting epithelial cancers: rational engineering, biochemical characterization, drug loading and cell delivery. 61
30706922 2019
35
Follicle-Stimulating Hormone Is an Autocrine Regulator of the Ovarian Cancer Metastatic Niche Through Notch Signaling. 61
30680340 2019
36
IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells. 61
30610060 2019
37
Development and validation of an improved diced electrophoresis gel assay cutter-plate system for enzymomics studies. 61
29928991 2019
38
KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling. 61
30115976 2019
39
Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report. 61
30723561 2019
40
Methotrexate-induced apoptosis in human ovarian adenocarcinoma SKOV-3 cells via ROS-mediated bax/bcl-2-cyt-c release cascading. 61
30588027 2019
41
Increased 131I Accumulation in the Gallbladder and High-grade Serous Ovarian Adenocarcinoma. 61
30371583 2019
42
Anti-neoplastic effect of mangiferin on human ovarian adenocarcinoma OVCAR8 cells via the regulation of YAP. 61
30655860 2019
43
Methylation of the first exon in the erythropoietin receptor gene does not correlate with its mRNA and protein level in cancer cells. 61
30606107 2019
44
Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells. 61
31825993 2019
45
[Paraneoplastic neurologic degeneration revealing ovarian cancer recurrence]. 61
31692829 2019
46
Use of the term atypical cells in the reporting of ascitic fluid cytology: A caveat. 61
31367221 2019
47
Solid-liquid Interface Screening SystemーApplication to the Screening of Antibiotic and Cytotoxic Substance-producing Fungi. 61
30880313 2019
48
Dual functions for OVAAL in initiation of RAF/MEK/ERK prosurvival signals and evasion of p27-mediated cellular senescence. 61
30478051 2018
49
Preventative effect of celecoxib in dimethylbenz[a]anthracene-induced ovarian cancer in rats. 61
30242499 2018
50
Paraneoplastic Cerebellar Degeneration Associated With Ovarian Adenocarcinoma: A Case Report and Review of Literature. 61
30532364 2018

Variations for Ovary Adenocarcinoma

ClinVar genetic disease variations for Ovary Adenocarcinoma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ERBB2 NM_004448.3(ERBB2):c.2570A>G (p.Asn857Ser)SNV Pathogenic/Likely pathogenic 13880 rs28933370 17:37881378-37881378 17:39725125-39725125

Copy number variations for Ovary Adenocarcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 118124 17 7571720 7590868 Mutation TP53 Ovarian adenocarcinomas

Expression for Ovary Adenocarcinoma

Search GEO for disease gene expression data for Ovary Adenocarcinoma.

Pathways for Ovary Adenocarcinoma

Pathways related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.93 TP53 KRAS HRAS ERBB2 CTNNB1 BRCA1
2
Show member pathways
12.82 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
3 12.79 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
4
Show member pathways
12.67 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
5
Show member pathways
12.59 TP53 KRAS HRAS ERBB2 BAX
6
Show member pathways
12.59 TP53 KRAS HRAS ERBB2 BRCA1 BAX
7
Show member pathways
12.44 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
8
Show member pathways
12.42 TP53 KRAS HRAS ERBB2 CTNNB1 BRCA1
9
Show member pathways
12.36 KRAS HRAS CTNNB1 BRCA1
10
Show member pathways
12.34 TP53 MIR17 BRCA1 BAX
11 12.3 TP53 KRAS HRAS BAX
12
Show member pathways
12.28 KRAS HRAS ERBB2 CTNNB1
13 12.27 TP53 KRAS HRAS BAX
14
Show member pathways
12.27 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
15
Show member pathways
12.25 TP53 HRAS ERBB2 CTNNB1 BAX
16 12.23 TP53 KRAS HRAS ERBB2 CTNNB1
17
Show member pathways
12.19 TP53 KRAS HRAS ERBB2 BAX
18 12.16 TP53 KRAS CTNNB1 BAX
19
Show member pathways
12.11 TP53 KRAS HRAS BAX
20
Show member pathways
12.1 TP53 KRAS HRAS BAX
21 12.07 KRAS INHBA HRAS CTNNB1
22 11.99 TP53 KRAS CTNNB1 BRCA1 BAX
23 11.98 TP53 KRAS HRAS CTNNB1
24 11.95 TP53 KRAS HRAS BAX
25 11.91 TP53 KRAS HRAS CTNNB1
26
Show member pathways
11.77 KRAS HRAS BAX
27 11.74 TP53 KRAS BAX
28 11.72 TP53 MIR30A MIR17 MIR135A1 KRAS HRAS
29 11.67 TP53 KRAS HRAS
30 11.66 TP53 ERBB2 BRCA1 BAX
31 11.64 TP53 KRAS HRAS ERBB2
32 11.6 TP53 KRAS HRAS ERBB2
33 11.59 INHBA HRAS CTNNB1
34 11.58 KRAS HRAS ERBB2
35 11.49 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
36 11.47 TP53 BRCA1 BAX
37 11.47 TP53 HRAS ERBB2 BRCA1 ARID1A
38 11.1 KRAS HRAS ERBB2 CTNNB1

GO Terms for Ovary Adenocarcinoma

Cellular components related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 8.92 MIR30A MIR17 MIR135A1 MIR1307

Biological processes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10 TP53 INHBA ERBB2 CTNNB1 BRCA1 ARID1A
2 negative regulation of cell proliferation GO:0008285 9.88 TP53 INHBA HRAS CTNNB1 BAX
3 Ras protein signal transduction GO:0007265 9.67 TP53 KRAS HRAS
4 positive regulation of MAP kinase activity GO:0043406 9.63 KRAS HRAS ERBB2
5 nervous system development GO:0007399 9.63 INHBA ESS2 ERBB2 CTNNB1 BAX ARID1A
6 positive regulation of neuron apoptotic process GO:0043525 9.58 TP53 CTNNB1 BAX
7 response to salt stress GO:0009651 9.51 TP53 BAX
8 response to isolation stress GO:0035900 9.43 KRAS HRAS
9 androgen receptor signaling pathway GO:0030521 9.43 CTNNB1 BRCA1 ARID1A
10 regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902108 9.37 TP53 BAX
11 cellular response to indole-3-methanol GO:0071681 9.32 CTNNB1 BRCA1
12 positive regulation of gene expression GO:0010628 9.23 TP53 MIR30A KRAS INHBA HRAS ERBB2
13 intrinsic apoptotic signaling pathway GO:0097193 9.13 TP53 HRAS BAX

Sources for Ovary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....